Dr. Reddys Laboratories Ltd.

Foreign institutional investors (FIIs) have raised their stake in Dr Reddy’s Laboratories by 312 basis points to 38.41 percent in Q2FY15 from 35.29 percent as on June 30, 2014. However, domestic institutional investors (DIIs) have reduced their shareholding in the company by 5 basis points to 5.38 percent at the end of September 2014 quarter from 5.43 percent as on June 30, 2014.

Meanwhile, non institutions were holding 13.68 percent stake in the company at the end of September 2014 quarter, down 165 basis points from 15.33 percent as on June 30, 2014. While, corporate bodies were holding 4.55 percent stake in the company at the end of September 2014 quarter, down 126 basis points from 5.81 percent as on June 30, 2014.

Dr. Reddys is an integrated global pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives. Through its three businesses - Pharmaceutical Services and Active Ingredients, Global Generics and Proprietary Products - the company offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, bio-similars, differentiated formulations and NCEs.